CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Krsnaa Diagnostics has commenced its fourth out of eight Diagnostics Center in Ayodhya
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Gafchromic films support patient care in oncology
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The blood test market worldwide is today around $75-80 billion
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Subscribe To Our Newsletter & Stay Updated
